DaVita Inc. (NYSE:DVA) Given Consensus Rating of “Hold” by Analysts

Shares of DaVita Inc. (NYSE:DVA) have earned a consensus rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $155.80.

A number of brokerages recently weighed in on DVA. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. UBS Group upped their price target on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Barclays boosted their target price on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th.

DaVita Price Performance

DaVita stock opened at $158.06 on Monday. The company has a market cap of $10.56 billion, a price-to-earnings ratio of 15.73, a price-to-earnings-growth ratio of 0.55 and a beta of 0.93. DaVita has a 12 month low of $101.00 and a 12 month high of $157.91. The stock’s 50-day moving average is $124.18 and its 200-day moving average is $125.91.

DaVita (NYSE:DVA) last posted its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. The firm had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company’s revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Research analysts anticipate that DaVita will post 10.76 EPS for the current year.

Institutional Investors Weigh In On DaVita

A number of hedge funds have recently bought and sold shares of the business. Invesco Ltd. boosted its stake in shares of DaVita by 2.0% during the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after buying an additional 32,358 shares during the last quarter. Morgan Stanley boosted its stake in DaVita by 5.1% during the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock valued at $167,807,000 after acquiring an additional 71,156 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after acquiring an additional 636,191 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of DaVita by 0.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,089,100 shares of the company’s stock worth $123,733,000 after purchasing an additional 3,507 shares during the last quarter. Finally, LSV Asset Management raised its stake in shares of DaVita by 1.1% in the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock valued at $106,426,000 after purchasing an additional 9,739 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.